Precisio Biotix Therapeutics Inc. has entered into an agreement with Mayo Clinic that will include co-development of novel precision antibacterials targeting indications prone to antimicrobial-resistant (AMR) infections. Precisio creates lower cost novel precision biological antibacterials with a focus on lung and skin infections.
The use of latency reversing agents is useful for reducing the HIV reservoir, but their effect on infected cells isolated from untreated people with HIV is still unknown.
At this week’s ACS meeting in New Orleans, Fimbrion Therapeutics Inc. presented the rational design of a different series of small-molecule biaryl O- and C-linked mannoside-based inhibitors of the virulence factor FimH, as potential agents for the treatment of urinary tract infections (UTIs).